387 related articles for article (PubMed ID: 21979952)
1. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
2. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
3. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
4. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
[TBL] [Abstract][Full Text] [Related]
5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
6. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
7. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
8. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
9. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
[TBL] [Abstract][Full Text] [Related]
10. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
11. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
12. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
[TBL] [Abstract][Full Text] [Related]
13. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
[TBL] [Abstract][Full Text] [Related]
14. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
Milton FA; Cvoro A; Amato AA; Sieglaff DH; Filgueira CS; Arumanayagam AS; de Lima Mdo C; Pitta IR; de Assis Rocha Neves F; Webb P
Biochem Biophys Res Commun; 2015 Aug; 464(3):718-23. PubMed ID: 26168725
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
16. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
[TBL] [Abstract][Full Text] [Related]
18. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
19. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
20. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]